




















WHO International Biological Reference Preparations

Held and Distributed by the WHO International Laboratories for Biological Standards


VACCINES / TOXOIDS / TOXINS

PREPARATION	STANDARD	MATERIAL	HELD AT	CODE	WHO/BS DOCUMENT	
● Acellular pertussis vaccine for potency assay by modified mouse challenge test, Lyophilized, 34 IU / ampoule	1st International Standard, 2008	Vaccine	NIBSC	JNIH-3	08.2086	
● Anthrax spore vaccine, Lyophilized spore suspension of Bacillus anthracis strain 34 F2., 1 IU / ampoule.	1st International Reference Preparation, 1978	Antigen	NIBSC	AxV2	78.1198	
● Anti-brucella abortus serum, bovine, Lyophilized, 1,000 IU / ampoule of agglutinating; 1,000 IU / ampoule of complement-fixing activity.	2nd International Standard, 1975	Ovine serum	NIBSC	BaDS	75.1124	
● Anti-dengue virus type 1,2,3 and 4 serum, Freeze-dried, 100 units per serotype per ampoule.	1st Reference Reagent, 2005	Human plasma	NIBSC	02/186	05.2009	
● BCG vaccine, Lyophilized, 2.5 mg of semi-dry bacillary mass / 5-ml ampoule.	1st International Reference Preparation, 1965	Antigen	NIBSC	BCG	65.802	
● BCG, Danish 1331 sub-strain for viability, identity and in vivo assays, Lyophilized,	1st Reference Reagent, 2009	Bacteria	NIBSC	07/270	09.2114	
● BCG, Russian BCG-I sub-strain for viability, identity and in vivo assays, Lyophilized,	1st Reference Reagent, 2010	Bacteria	NIBSC	07/274	10.2148, 09.2114	
● BCG, Tokyo 172 sub-strain for viability, identity and in vivo assays, Lyophilized,	1st Reference Reagent, 2009	Bacteria	NIBSC	07/272	09.2114	
● Bordetella pertussis fimbrial antigen type 2 (monoclonal antibody for serotyping). Lyophilized. No assigned values, ,	1st International Standard, 2009	Cell culture suspension	NIBSC	06/124	09.2120	
● Bordetella pertussis fimbrial antigen type 3 (monoclonal antibody for serotyping). Lyophilized. No assigned values, ,	1st International Standard, 2009	cell culture suspension	NIBSC	06/128	09.2120	
● Cholera vaccine (Inaba), Lyophilized, 40,000,000,000 organisms / ampoule.	2nd International Reference Preparation, 1971	Antigen	NIBSC	INV	71.1032 Rev. 1	
● Cholera vaccine (Ogawa), Lyophilized, 40,000,000,000 organisms / ampoule.	2nd International Reference Preparation, 1971	Antigen	NIBSC	OGV	71.965	
● Clostridium novyi alpha toxoid, Lyophilized, No unitage assigned.	1st International Reference Preparation, 1966	Toxoid	NIBSC	CoT	70.1022	
● Clostridium perfringens beta toxoid, Lyophilized, No unitage assigned.	1st International Reference Preparation, 1975	Toxoid	NIBSC	CWBetatd	75.1122	
● Clostridium perfringens epsilon toxoid, Lyophilized, No unitage assigned.	1st International Reference Preparation, 1975	Antigen	NIBSC	CW Epsilontd	75.1122	
● Diphtheria (schick) test toxin, Lyophilized, 900 IU / ampoule.	1st International Standard, 1954	Toxin	NIBSC	STT	54.274	
● Diphtheria toxoid, absorbed, Lyophilized, 160 IU / ampoule.	3rd International Standard, 1999	Adsorbed toxoid	NIBSC	98/560	99.1915	
● Diphtheria Toxoid, absorbed, Lyophilized, 213 IU/ampoule	4th International Standard, 2009	Toxoid	NIBSC	07/216	09.2123	








VACCINES / TOXOIDS / TOXINS

PREPARATION	STANDARD	MATERIAL	HELD AT	CODE	WHO/BS DOCUMENT	
Diphtheria toxoid, for flocculation tests, Lyophilized, 1100 Lf IU / ampoule.	2nd International Standard, 2007	Toxoid	NIBSC	02/176 (DIFT)	07.2062	
Endotoxin for Limulus Amoebocyte Lysate (LAL) gelation tests, Lyophilized, 10,000 IU / ampoule.	2nd International Standard, 1996	Toxin	NIBSC	94/580	96.1830 Rev. 1	
Haemophilus influenzae type b capsular polysaccharide, Lyophilized, 4.933 ± 0.267 mg/ampoule of polyribosyl ribitol phosphate (PRP).	1st International Standard, 2005	Antigen	NIBSC	02/208	05.2018	
Hepatitis A vaccine, inactivated, Frozen, 100 IU / ml of immunogenic activity; 100 IU / ml of antigen content.	1st International Standard, 1999	Antigen	NIBSC	95/500	99.1914	
Human papillomavirus type 16 DNA, Lyophilized, 5 x 10**6 IU / ampoule	1st International Standard, 2008	DNA	NIBSC	06/202	08.2081	
Human papillomavirus type 18 DNA, Lyophilized, 5 x 10**6 IU / ampoule	1st International Standard, 2008	DNA	NIBSC	06/206	08.2081	
Human papillomavirus virus type 16, antibodies, Lyophilized, 5 International Units per ampoule	1st International Standard, 2009	Human plasma	NIBSC	05/134	09.2113	
Influenza H5N1 antibody (human), Lyophilized, 1,000 IU / ampoule	1st International Standard, 2008	Human serum	NIBSC	07/150	08/2085	
MAPREC analysis of Poliovirus type 1 (100% 480A/525C control), Liquid frozen 82.5% 480A,525C/vial, ,	1st Reference Reagent, 2009	Virus suspension	NIBSC	00/410	09.2103	
MAPREC analysis of Poliovirus type 1, (High mutant virus reference), Liquid frozen 2.56% 480A,525C/vial, ,	1st Reference Reagent, 2009	Virus suspension	NIBSC	00/422	09.2103	
MAPREC analysis of Poliovirus type 1, (Low mutant virus reference), Liquid frozen 1.84% 480A,525C/vial, ,	1st Reference Reagent, 2009	Virus suspension	NIBSC	00/416	09.2103	
MAPREC analysis of poliovirus type 3 (Sabin), Lyophilized, 0.9% 472-C nucleotide / vial.	1st International Standard, 1996	Chemically synthesized DNA	NIBSC	95/542	96.1841	
MAPREC analysis of poliovirus type 3 (Sabin), high virus reference, Lyophilized, 1.1% 472-C nucleotide / vial.	1st Reference Reagent, 1997	Chemically synthesized DNA	NIBSC	96/578	97.1865	
MAPREC analysis of poliovirus types 3 (Sabin), low virus reference, Lyophilized, 0.7% 472-C nucleotide / vial.	1st Reference Reagent, 1997	Chemically synthesized DNA	NIBSC	96/572	97.1865	
MAPREC assay for poliovirus type 2, Lyophilized, 0.67% 481-G per ampoule.	1st International Standard, 2003	Chemically synthesized DNA	NIBSC	97/758	03.1957	
MAPREC assay of poliovirus type 2 (481-G control), Lyophilized, 93.5% 481-G per ampoule.	1st Reference Reagent, 2003	Chemically synthesized DNA	NIBSC	98/524	03.1957	
MAPREC assay of poliovirus type 2 (high mutant virus), Lyophilized, 1.21% 481-G per ampoule.	1st Reference Reagent, 2003	Chemically synthesized DNA	NIBSC	98/596	03.1957	
MAPREC assay of poliovirus type 2 (low mutant virus), Lyophilized., 0.65% 481-G per ampoule.	1st Reference Reagent, 2003	Chemically synthesized DNA	NIBSC	97/756	03.1957	
Measles vaccine (live), Lyophilized, 4.3 log10 (20 000) infectious units / vial.	2nd International Reference Reagent, 1994	Attenuated measles virus	NIBSC	92/648	94.1771	

VACCINES / TOXOIDS / TOXINS

PREPARATION	STANDARD	MATERIAL	HELD AT	CODE	WHO/BS DOCUMENT
Mumps vaccine (live), Lyophilized, 4.6 log ₁₀ (40000) infectious units / vial.	1st International Reference Reagent, 1994	Attenuated mumps virus	NIBSC	90/534	94.1772
Mycobacterium bovis BCG vaccine (Danish strain) Lyophilized. 72.9 million colony forming units or 56.06 ng ATP per ampoule, ,	1st Reference Reagent, 2009	Antigen	NIBSC	07/270	09.2114 
Mycobacterium bovis BCG vaccine (Moscow I strain) Lyophilized. 3.39 colony forming units or 7.52 ng ATP per ampoule, ,	1st Reference Reagent, 2009	Antigen	NIBSC	07/274	09.2114 
Mycobacterium bovis BCG vaccine (Tokyo strain) Lyophilized. 49.37 million colony forming units or 217.60 ng ATP per ampoule, ,	1st Reference Reagent, 2009	Antigen	NIBSC	07/272	09.2114 
Newcastle disease vaccine (inactivated), Lyophilized, 525 IU / ampoule.	1st International Standard, 1963	Antigen	NIBSC	NVIA	63.626
Opacity, , 10 IU of opacity.	5th International Standard, 1975	Miscellaneous	NIBSC	76/522	75.1119
Pertussis antiserum (human), anti-PT IgG, Lyophilized, 335 IU and anti-PT IgA 65 IU / ampoule; anti-FHA IgG 130 IU and anti-FHA IgA 65 IU / ampoule; anti-69K IgG 65 IU and anti-PT IgA 42 IU / ampoule	1st International Standard, 2008	Human serum	NIBSC	06/140	08.2083 
Pertussis serotype 2, typing serum (anti-Bordetella pertussis fimbriae), , No assigned value.	1st Reference Reagent, 2004	Monoclonal IgG (mouse)	NIBSC	04/154	04.1998 
Pertussis serotype 3, typing serum (anti-Bordetella pertussis fimbriae), Frozen, No assigned value.	1st Reference Reagent, 2004	Monoclonal IgG (mouse)	NIBSC	04/156	04.1998 
Pertussis toxin, purified, Lyophilized, 10000 IU / ampoule.	1st International Standard, 2003	Toxin	NIBSC	JNIH-5	03.1978 
Pertussis vaccine (whole cell) 41S, Lyophilized, 40 IU / ampoule.	4th International Standard, 2006	Inactivated bordetella pertussis	NIBSC	94/532	06.2036 
Poliomyelitis vaccine (inactivated), Lyophilized, Type 1 antigen: 430 D-antigen units / ml, Type 2 antigen: 95 D-antigen units / ml, Type 3 antigen: 285 D-antigen units / ml.	1st International Reference Reagent, 1994	Inactivated polioviruses	NIBSC	91/574	94.1777
Poliomyelitis vaccine, oral, Frozen, 7.51 log ₁₀ TCID ₅₀ /ml poliovirus type 1. 6.51 log ₁₀ TCID ₅₀ /ml poliovirus type 2. 6.87 log ₁₀ TCID ₅₀ /ml poliovirus type 3. 7.66 log ₁₀ TCID ₅₀ /ml total poliovirus content.	2nd International Standard for potency testing, 2004	Antigen	NIBSC	02/306	04.1992 
Rabies vaccine, Lyophilized, 8 IU / ampoule for the in vivo mouse challenge assay; 3.3 IU glycoprotein antigen / ampoule for in vitro assays.	6th International Standard, 2008	Vaccine	NIBSC	07/162 (RAV)	08.2087 
Rubella vaccine (live), Lyophilized, 3.9 log ₁₀ (8 000) infectious units / vial.	1st International Reference Reagent, 1994	Attenuated rubella virus	NIBSC	91/688	94.1773
Smallpox vaccine, Lyophilized, 14 mg / ampoule.	1st International Standard, 1962	Antigen	NIBSC	SMV	61.536
Tetanus toxoid (absorbed) for potency assay, Lyophilized, 490 IU / ampoule.	4th International Standard, 2010	Toxoid	NIBSC	08/218	10.2150 
Tetanus toxoid, for flocculation tests, Lyophilized, 690 Lf / ampoule.	2nd International Standard, 2010	Toxoid	NIBSC	04/150 (TEFT)	07.2061, 10.2136 

VACCINES / TOXOIDS / TOXINS

PREPARATION	STANDARD	MATERIAL	HELD AT	CODE	WHO/BS DOCUMENT
 Tuberculin, old, Liquid, 90,000 IU / ml.	3rd International Standard, 1965	Mycobacterium tuberculosis culture derived	NIBSC	TU	65.779
 Tuberculin, purified protein derivative (PPD), avian, Lyophilized, 500,000 IU / ampoule.	1st International Standard, 1954	Mycobacterium avium culture derived	NIBSC	PPDA	53.227
 Tuberculin, purified protein derivative (PPD), bovine, Lyophilized, 58,500 IU / ampoule.	1st International Standard, 1986	Mycobacterium bovis culture derived	NIBSC	PPD BOV	86.1518
 Tuberculin, purified protein derivative (PPD), mammalian, Lyophilized, 5,000 IU / ampoule.	1st International Standard, 1951	Mycobacterium tuberculosis culture derived	NIBSC	PPDT	51.127
 Typhoid vaccine (acetone-inactivated), Lyophilized, No unitage assigned.	1st International Reference Preparation, 1960	Inactivated salmonella typhi	NIBSC	TYVK	60.515
 Typhoid vaccine (heat-phenol-inactivated), Lyophilized, No unitage assigned.	1st International Reference Preparation, 1960	Inactivated salmonella typhi	NIBSC	TYVL	60.515
 Yellow fever vaccine, Lyophilized, 4.5 log 10 IU / ampoule.	1st International Standard, 2003	Attenuated yellow fever virus	NIBSC	99/616	03.1985 Rev.1